Disclosed are compositions and methods for treating microbial inflammation including its end-stage sepsis and conditions associated with the microbial inflammation such as thrombocytopenia and hypoglycogenemia. In one aspect, the compositions and methods disclosed herein can also be used to enhance clearance of microbes from infected tissues, organs, or systems in a subject. Also disclosed herein are compositions and methods for reducing levels of stress responsible transcription factors and metabolic transcription factors in a cell in a subject with microbial inflammation.

The invention provides compositions and methods of modulating and regulating the activity of, expression of, or level of Nr2c2, to thereby modulate T regulatory cell (Treg) differentiation, function, activity, or maturation, or combinations of these biological activities. Such modulation may be useful in methods of treating and preventing cancer, inflammation, and inflammatory diseases, among other diseases, conditions, and illnesses.

The invention provides compositions and methods of modulating and regulating the activity of, expression of, or level of Nr2c2, to thereby modulate T regulatory cell (Treg) differentiation, function, activity, or maturation, or combinations of these biological activities. Such modulation may be useful in methods of treating and preventing cancer, inflammation, and inflammatory diseases, among other diseases, conditions, and illnesses.

The present disclosure provides methods for ameliorating or treating a neurological condition or disease in a subject in need of treatment thereof by administering to the subject a therapeutically effective amount of a composition comprising (i) a recombinant DNA (rDNA), wherein the rDNA comprises a human nuclear hormone receptor (hNHR) gene or a fragment thereof; and (ii) a delivery vehicle adapted for delivering said rDNA to neurological cells or tissues to ameliorate or treat said neurological condition or disease.

Disclosed herein are methods of increasing numbers of monocytes to a tumor or cancer metastasis site in a subject. Non-limiting embodiments include administering or using a Nur77 polypeptide or subsequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14+ CD16.sup.+ monocytes and/or CD14dimCD16.sup.+(CD115.sup.+CD11b.sub.+GR1.sup.?(Ly6C?)) monocytes; CD14.sup.+CD16.sup.+ monocytes and/or CD14dimCD16.sup.+(CD115.sup.+CD11b.sup.+GR1.sup.?(Ly6C?)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist. Also disclosed herein are methods of increasing, stimulating, activating or promoting monocyte migration to or mobilization against a tumor or cancer metastasis in a subject. Non-limiting embodiments include administering a Nur77 polypeptide or sub-sequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14+ CD16+ monocytes and/or CD14dimCD16.sup.+(CD115.sup.+CD11b.sup.+GR1.sup.? (Ly6C?)) monocytes; or CD14.sup.+CD16.sup.+ monocytes and/or CD14dimCD16.sup.+(CD115.sup.+CD11b.sup.+GR1.sup.?(Ly6C?)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist.

The present invention relates to compositions and methods comprising administering gene modifiers for treating ocular disease.

Provided are compositions for modulating molecules in a cell. Also provided are methods for modulating molecules in a cell.

The present invention relates to compositions and methods comprising administering gene modifiers for treating ocular disease.

This document relates to AAV vectors (e.g., AAV2 vectors). For example, AAV vectors (e.g., AAV2 vectors) containing an AAV capsid polypeptide that includes an amino acid sequence set forth in Table 1 (or a variant thereof) or Formula A, such AAV capsid polypeptides, nucleic acid molecules encoding such vectors, nucleic acid molecules encoding such AAV capsid polypeptides, host cells containing and/or expressing such nucleic acid molecules, and methods and materials for making or using such vectors and/or AAV capsid polypeptides are provided.

This document relates to AAV vectors (e.g., AAV2 vectors). For example, AAV vectors (e.g., AAV2 vectors) containing an AAV capsid polypeptide that includes an amino acid sequence set forth in Table 1 (or a variant thereof) or Formula A, such AAV capsid polypeptides, nucleic acid molecules encoding such vectors, nucleic acid molecules encoding such AAV capsid polypeptides, host cells containing and/or expressing such nucleic acid molecules, and methods and materials for making or using such vectors and/or AAV capsid polypeptides are provided.